{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:52:03Z","timestamp":1784019123034,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Autologous stem cell transplant (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>) is the current standard of care for most patients with multiple myeloma (MM) who are transplant eligible, yet the timing of<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>is disputed due to a similar overall (OS) and progression\u2010free survival with an early<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>(<jats:styled-content style=\"fixed-case\">eASCT<\/jats:styled-content>) or a delayed<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>(<jats:styled-content style=\"fixed-case\">dASCT<\/jats:styled-content>) approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We developed a decision analytic model to perform cost\u2010effectiveness analysis of the two commonly used treatment strategies for<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data on disease progression and treatment effectiveness came from 2001 to 2008 cohort treated at the Mayo Clinic and from published studies. Cost analysis was performed from a third\u2010party payer perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The Consumer Price Index adjusted 2012 costs of<jats:styled-content style=\"fixed-case\">eASCT<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">dASCT<\/jats:styled-content>were $249\u00a0236 and $262\u00a0610, respectively.<jats:styled-content style=\"fixed-case\">eASCT<\/jats:styled-content>cohort had a benefit of 1.96 quality\u2010adjusted life years (QALYs), 0.23 QALYs more than<jats:styled-content style=\"fixed-case\">dASCT<\/jats:styled-content>, implying that<jats:styled-content style=\"fixed-case\">eASCT<\/jats:styled-content>is preferred (dominant) over<jats:styled-content style=\"fixed-case\">dASCT<\/jats:styled-content>. The most critical variables in one\u2010way sensitivity analysis were treatment\u2010related mortality and OS associated with<jats:styled-content style=\"fixed-case\">eASCT<\/jats:styled-content>strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We conclude that<jats:styled-content style=\"fixed-case\">eASCT<\/jats:styled-content>could potentially be a relatively cost\u2010effective treatment option for appropriate patients with MM, and these results would help patients, providers, and payers in decision making for timing of ASCT.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ctr.12421","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T08:05:38Z","timestamp":1405584338000},"page":"1084-1091","source":"Crossref","is-referenced-by-count":23,"title":["Cost\u2010effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma"],"prefix":"10.1111","volume":"28","author":[{"given":"Chintan","family":"Pandya","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences University of Rochester Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Transplant Center Mayo Clinic Rochester MN USA"},{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Khera","sequence":"additional","affiliation":[{"name":"Hematology Oncology\/Blood and Marrow Transplant Mayo Clinic Arizona Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Transplant Center Mayo Clinic Rochester MN USA"},{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Transplant Center Mayo Clinic Rochester MN USA"},{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hogan","sequence":"additional","affiliation":[{"name":"Transplant Center Mayo Clinic Rochester MN USA"},{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustaqeem","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Transplant Center Mayo Clinic Rochester MN USA"},{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Noyes","sequence":"additional","affiliation":[{"name":"Surgical Health Outcomes and Research Enterprise (SHORE) University of Rochester Rochester NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Transplant Center Mayo Clinic Rochester MN USA"},{"name":"Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides","author":"Pasquini MC","year":"2013"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26422"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3131"},{"key":"e_1_2_6_5_1","volume-title":"Stratification for Myeloma And Risk\u2010adapted Therapy (mSMART)","author":"Consensus Guidelines to Management of Plasma Cell Disorders"},{"key":"e_1_2_6_6_1","volume-title":"British Committee for Standards in Haematology in conjunction with the UK Myeloma Forum (UKMF) Guidelines on the Management and Diagnosis of Multiple Myeloma","year":"2010"},{"key":"e_1_2_6_7_1","volume-title":"Myeloma","author":"National Comprehensive Cancer Network"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq178"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703676"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-426783"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075047"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-12-200806170-00222"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs A","year":"2006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540140060028"},{"key":"e_1_2_6_15_1","unstructured":"U.S. Bureau of Labor Statistics.http:\/\/www.bls.gov\/bls\/inflation.htm(accessed 04\/2013)."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.64"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01153.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01624.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.3324.3324"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0889"},{"key":"e_1_2_6_22_1","first-page":"1159","article-title":"A cost\u2010utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem\u2010cell rescue","volume":"40","author":"Agthoven M","year":"2004","journal-title":"Eur J Cancer"},{"key":"e_1_2_6_23_1","first-page":"68","volume-title":"The Economics of Health and Health Care","author":"Folland S","year":"2010"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1202819"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0171"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-297325"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa044278"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300102077"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0380"},{"key":"e_1_2_6_32_1","first-page":"492","article-title":"What is the price benchmark to replace average wholesale price (AWP)?","volume":"16","author":"Curtiss FR","year":"2010","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_6_33_1","unstructured":"Department of Health and Human Services.Office of Inspector General (OIG) Report\u2018Replacing Average Wholesale Price: Medicaid Drug Payment Policy\u2019.https:\/\/oig.hhs.gov\/oei\/reports\/oei-03-11-00060.pdf(accessed 03\/2013)."},{"key":"e_1_2_6_34_1","unstructured":"Medicare Part B Drug Average Sales Price:http:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice\/index.html?redirect=\/mcrpartbdrugavgsalesprice\/(accessed 03\/2013)."},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/2152-2812.1114","article-title":"Skills of the trade: the Tufts cost\u2010effectiveness analysis registry","volume":"3","author":"Thorat T","year":"2012","journal-title":"J Bene\u2010Cost Anal"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.12421","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.12421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T15:08:21Z","timestamp":1717081701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.12421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/ctr.12421"],"URL":"https:\/\/doi.org\/10.1111\/ctr.12421","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,18]]}}}